dubi said:
Kiddoc,
Your thoughts on RSV vaccine for seniors? Mom is 91 and healthy; should she get it?
No idea really but the data supporting them is pretty dang strong. I would get it.
From OpenEvidence AI:
RSV protein subunit vaccines (GSK Arexvy/RSVPreF3+AS01 and Pfizer Abrysvo/RSVpreF) have demonstrated moderate-to-high efficacy against RSV-associated lower respiratory tract disease (LRTD) in adults 60 years, with prelicensure trial efficacy ranging roughly 6783% and strong real-world effectiveness against hospitalization.[url=https://pubmed.ncbi.nlm.nih.gov/37471262][1][/url][url=https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.34788?utm_source=openevidence&utm_medium=referral][2][/url][url=https://pubmed.ncbi.nlm.nih.gov/41771131][3][/url]
Prelicensure trial efficacy (first season, 60 years)-
RSVPreF3+AS01 (Arexvy): 82.6% (95% CI, 57.9%94.1%) against RSV-associated LRTD.[url=https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.34788?utm_source=openevidence&utm_medium=referral][2][/url]
-
RSVpreF (Abrysvo): 66.7% (95% CI, 28.8%85.8%) against LRTD with 2 symptoms and 85.7% (95% CI, 32.0%98.7%) with 3 symptoms; 62.1% against any acute symptomatic RSV including URTD.[url=https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2026.34788?utm_source=openevidence&utm_medium=referral][2][/url][url=https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.7406?utm_source=openevidence&utm_medium=referral][4][/url]
-
Durability: In the Abrysvo phase 3 trial, efficacy against LRTD with 3 symptoms was 88.9% at end of season 1 and 77.8% at end of season 2, indicating durable but modestly waning protection over two seasons, with robust neutralizing responses across age strata (6069, 7079, 80) and chronic conditions.[url=https://pubmed.ncbi.nlm.nih.gov/39928572][5][/url]
Pooled/meta-analytic efficacy (ACP rapid review)Protein subunit vaccines in older adults probably reduce RSV-related hospitalization (VE 83.3%; 95% CI, 42.9%96.9%; moderate certainty) and severe RSV illness (VE 94.1%; 95% CI, 62.4%99.9%; moderate certainty), but have no effect on all-cause mortality (RR 1.07; 95% CI, 0.681.68; high certainty).[url=https://pubmed.ncbi.nlm.nih.gov/41771131][3][/url]
Real-world effectivenessPostlicensure observational studies show vaccine effectiveness against RSV-associated hospitalization ranging from 75% (95% CI, 50%87%) to 82% (95% CI, 69%89%) in the first season, with similar protection across both products, across ages 6074 and 75 years, and in immunocompromised adults and those with end-stage renal disease.[url=https://doi.org/10.15585/mmwr.mm7332e1][6][/url][url=https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.15775?utm_source=openevidence&utm_medium=referral][7][/url] Effectiveness has also been demonstrated in nursing home residents and against RSV-associated ED/urgent care visits and thromboembolic events.[url=https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2026.3841?utm_source=openevidence&utm_medium=referral][8][/url]
Safety contextSerious adverse events did not differ from placebo (RR 0.96; 95% CI, 0.751.23).[url=https://pubmed.ncbi.nlm.nih.gov/41771131][3][/url] However, postlicensure FDA self-controlled analyses raised a possible small excess risk of
Guillain-Barr syndrome within 42 days (adjusted IRR 2.30 for Arexvy, 4.48 for Abrysvo; both with wide, non-significant CIs) among Medicare beneficiaries 65 years.[url=https://doi.org/10.15585/mmwr.mm7332e1][6][/url]
The cumulative-incidence curve below from a recent RSVpreF randomized trial illustrates the early and sustained separation underlying the 83.3% effectiveness against RSV-related hospitalization in older adults.

Figure 2 Hospitalization for RSV-Related Respiratory Tract Disease. Time-to-event curves for the primary end point according to trial group are shown. Vaccine effectiveness was calculated by subtracting the incidence rate ratio for end-point events in the RSVpreF group as compared with the control group from 1 and multiplying by 100 to obtain a percentage. The inset displays the same data with an expanded y axis.
Current ACIP guidance (updated June 2024) recommends a single dose for all adults 75 years and for adults 6074 years at increased risk of severe RSV disease.[url=https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.15775?utm_source=openevidence&utm_medium=referral][7][/url][url=https://doi.org/10.1111/jgs.19243][10][/url]
Would you like to explore how the Moderna mRNA RSV vaccine compares to the protein subunit vaccines in older adults?
References
[ol]
Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023. Melgar M, Britton A, Roper LE, et al. MMWR. Morbidity and Mortality Weekly Report. 2023;72(29):793-801. doi:10.15585/mmwr.mm7229a4.Respiratory Syncytial Virus Vaccine Effectiveness Among US Older Adults, 2023-2024 Season. Lu Y, Smith ER, McEvoy R, et al. JAMA Network Open. 2026;9(9):e2634788. doi:10.1001/jamanetworkopen.2026.34788.Efficacy, Comparative Effectiveness, and Harm of Respiratory Syncytial Virus Vaccines in Adults Who Are Not Pregnant or Immunocompromised: A Rapid Review for the American College of Physicians. Moser ITK, Dobrescu AI, Sommer I, et al. Annals of Internal Medicine. 2026;179(5):685-695. doi:10.7326/ANNALS-25-05536.Therapies to Decrease Severe Respiratory Syncytial Virus Illness. Scruggs-Wodkowski EA, Malani PN, Linder KA. JAMA. 2024;331(24):2127-2128. doi:10.1001/jama.2024.7406.Efficacy, Immunogenicity, and Safety of the Bivalent Respiratory Syncytial Virus (RSV) Prefusion F Vaccine in Older Adults Over 2 RSV Seasons. Walsh EE, Eiras D, Woodside J, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2026;81(6):e680-e689. doi:10.1093/cid/ciaf061.Use of Respiratory Syncytial Virus Vaccines in Adults Aged 60 Years: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2024. Britton A, Roper LE, Kotton CN, et al. MMWR. Morbidity and Mortality Weekly Report. 2024;73(32):696-702. doi:10.15585/mmwr.mm7332e1.RSV Vaccine Effectiveness Against Hospitalization Among US Adults 60 Years and Older. Surie D, Self WH, Zhu Y, et al. JAMA. 2024;332(13):1105-1107. doi:10.1001/jama.2024.15775.Respiratory Syncytial Virus Vaccine Effectiveness in Medicare Beneficiaries Residing in Nursing Homes. Wiegand RE, Sung HM, Zhang Y, et al. JAMA Internal Medicine. 2026;:2853166. doi:10.1001/jamainternmed.2026.3841.RSV Prefusion F Vaccine for Prevention of Hospitalization in Older Adults. Lassen MCH, Johansen ND, Christensen SH, et al. The New England Journal of Medicine. 2026;394(2):138-151. doi:10.1056/NEJMoa2509810.Vaccinations in older adults: Optimization, strategies, and latest guidelines. Pangilinan AR, Brangman SA, Gravenstein S, Schmader K, Kuchel GA. Journal of the American Geriatrics Society. 2025;73(1):20-28. doi:10.1111/jgs.19243.[/ol]
No material on this site is intended to be a substitute for professional medical advice, diagnosis or treatment. See full
Medical Disclaimer.